Investigating how a specific protein affects nerve damage from chemotherapy
Damage-associated molecular patterns in chemotherapy toxicity
This study is looking at how a common cancer drug can cause nerve damage and pain, and it’s exploring a specific protein that might help reduce these side effects, so patients can feel better while getting their treatment.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11104906 on NIH RePORTER |
What this research studies
This research focuses on understanding the mechanisms behind nerve damage caused by the chemotherapy drug paclitaxel, which is commonly used to treat cancers like breast and lung cancer. The study aims to identify a protein called S100A9 that may play a role in this nerve damage and neuroinflammation. By exploring how inhibiting S100A9 can potentially reduce the side effects of paclitaxel, the research seeks to improve treatment outcomes for patients experiencing painful nerve damage. Patients may be involved in trials that test new therapies targeting this protein to alleviate their symptoms.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients receiving paclitaxel who are experiencing or at risk of developing peripheral neuropathy.
Not a fit: Patients who are not receiving paclitaxel or those with other types of neuropathy unrelated to chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce nerve damage and improve the quality of life for cancer patients undergoing chemotherapy.
How similar studies have performed: Previous research has shown promise in targeting similar molecular pathways to alleviate chemotherapy-induced side effects, suggesting potential for success in this approach.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Eisenmann, Eric Daniel — Ohio State University
- Study coordinator: Eisenmann, Eric Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.